Introduction
Mammalian lipid phosphate phosphatases (LPPs) were first characterized as Mg 2+ -independent and N-ethylmaleimide-insensitive phosphatidate phosphatases in 1991 (1) . These enzymes were called Type 2 phosphatidate phosphatases (PAP2) at this time to distinguish them from the Type 1 Mg 2+ -dependent phosphatidate phosphatases (PAP1). PAP1 enzymes exist in the cytosol of cells and they translocate to the endoplasmic reticulum where they produce diacylglycerol for glycerolipid synthesis (2).
It was not until 2006 that the structure of the PAP1 enzymes were identified in yeast and were shown to belong to a family of enzymes called lipins (3) . All three mammalian lipins have PAP1 activity are specific for phosphatidate as a substrate (4) .
By contrast, PAP2 enzymes dephosphorylate a wide variety of lipid phosphates including lysophosphatidate (LPA), sphingosine 1-phosphate (S1P), ceramide 1-phosphate (5), diacylglycerol pyrophosphate (6) and N-oleoylethanolamine phosphate (7) . Because of this broad specificity, the PAP2 enzymes were renamed as lipid phosphate phosphatases (8) . cDNA was cloned for mammalian LPP1 in 1996 (9) and LPP3 was identified a year later (10). The identities of genes that encode LPP1 and diacylglycerol pyrophosphate phosphatase (DPP1) in Saccharomyces cerevisiae were identified in 1998 lecithin:cholesterol acyltransferase in high-density lipoproteins (30). Saturated LPA can also be produced by secretory phospholipase A 2 (PLA 2 ), which hydrolyzes PA in microvesicles during inflammation (39) and platelet aggregation (40). However, a large proportion of circulating LPC is polyunsaturated and these LPCs are secreted by hepatocytes and probably by other cells (41, 42) . ATX preferentially catalyzes the hydrolysis of mono-and polyunsaturated LPC (42, 43). LPP1 activity is partly responsible for counter-balancing the signaling effects of ATX by degrading circulating LPA.
LPA signals to cells by stimulating at least six G-protein-coupled receptors (44, 45). The lack of LPA signaling in ATX knockout mice is embryonically lethal, since ATX and LPA are required for vasculogenesis and neural crest formation in embryos (46, 47). LPA also facilitates wound repair by stimulating platelet aggregation and the migration of fibroblasts, vascular smooth muscle cells, endothelial cells and keratinocytes into the wounded area (30). LPA mediates lymphocyte extravasation, which is crucial for maintaining immune homeostasis (48, 49). However, in chronically inflamed tissues, high LPA enhances lymphocyte invasion and increases cytokine production in response to repeated micro-injuries and incomplete tissue repair (50-52). LPA signaling plays a major role in neural development and repair (53), neuropathic pain (54), rheumatoid arthritis (55), fertility (38), obesity (56) and cancer (57). All of these actions of LPA could be impacted by LPP action, but this has not yet been investigated fully.
The ecto-activity of LPP1 in vivo has been demonstrated in LPP1 hypomorph mice (PPAP2A tr/tr ) (58), which have increased plasma LPA concentrations and a longer half-life for circulating LPA relative to the control mice (12 min versus 3 min). However, it is surprising that the circulating LPA concentrations were not significantly decreased in transgenic mice with LPP1 overexpression (38).
Fibroblasts from these transgenic mice responded less to LPA-stimulated migration (59, 60) and showed increased diacylglycerol (DG) accumulation in the cells after stimulation of PA production with phorbol ester (38). These fibroblasts also show 3-fold higher ecto-activity against LPA. Therefore, this unexpected result of circulating LPA in the transgenic mice may suggest a more complex mechanism of LPA regulation in the blood. There was no change in the expressions of LPP2, and LPP3 in the LPP1 hypomorph mice (58). However, it should be noted that the expression level of ATX was not measured in the LPP1 transgenic or LPP1 hypomorph mice. This could be important since ATX expression is controlled partly by negative feedback regulation from LPA (61).
The apparent K m (concentration needed to attain half maximum velocity) for the degradation of exogenous LPA by LPP1 in fibroblasts is about 36 µM (62), which is much higher than physiological concentrations of LPA (100 nM to 2 µM). This indicates that the LPPs can degrade LPA in proportion to its concentration over the physiological and pathological ranges. In addition, extracellular Ca explain some of the differences between results in vitro and in vivo. Salous et al. found that exogenous LPA injected into the circulation of mice is rapidly absorbed by non-parenchymal cells in the liver (63).
Our unpublished results showed the same phenomenon: after injecting [ 32 P]LPA into the circulation of rats, the radioactivity in plasma decreased rapidly and after 2 min and most of the radioactivity accumulated in the liver. Therefore, the liver probably acts as a powerful buffering system to regulate LPA levels in the blood.
Dephosphorylation of Extracellular S1P
S1P is the sphingolipid analogue of LPA, and it signals through its five G-protein coupled receptors (64) . S1P is present in plasma at concentrations from 100 nM to 1 µM (65). Circulatory S1P is bound to albumin, low-density lipoproteins and high-density lipoproteins. It can also be carried by erythrocytes (65) . S1P is formed inside cells through phosphorylation of sphingosine by sphingosine kinase-1 and -2 (66) . Different types of cells, including cancer cells and astrocytes, secrete S1P through the ATP-binding cassette (ABC) transporters, ABCC1, ABCG2, and ABCA1 (65, (67) (68) (69) and by protein spinster homolog-2 (70). S1P is dephosphorylated by two specific S1P phosphatases, which are expressed mainly on the endoplasmic reticulum rather than on the plasma membrane (23) . Extracellular S1P is cleared from blood in 15-30 min, and this process depends on a cellular phosphatase activity, but not on S1P-lyase (71) . This means that the LPPs should be a major regulator of external S1P concentrations.
Overexpression of LPP1 in HEK293 and human pulmonary artery endothelial cells leads to increased hydrolysis of extracellular S1P (72, 73) . The conversion of extracellular S1P to sphingosine by LPP-1 facilitates sphingosine uptake, followed by its intracellular conversion to S1P by sphingosine kinase-1 (72) . LPP3 is required for hydrolyzing thymic and cerebral S1P to maintain the normal functions of these organs (74, 75) . Studies on FTY720 also indicate a role for the LPPs as ecto-enzymes. FTY720
is an analogue of sphingosine that is used as an immunomodulatory drug for treating multiple sclerosis (76) . FTY720 is converted to FTY720-P by sphingosinne kinase-2 (77) . Results from cells that overexpress LPP1, -2 and -3 showed that only LPP3 dephosphorylates FTY720-P. LPP3 acted as an ectophosphatase in intact cells, to control the equilibrium between FTY720 and FTY720-P (77). This result is surprising compared to the broad substrate preference of the LPPs for lipid phosphates (31). Other studies show that LPP1a had the highest activity and affinity for FTY720-P (78). These results suggest that the first extracellular loop, which is different in LPP1a compared to LPP1, is involved in substrate recognition.
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Dephosphorylation of Other Extracellular Lipid Phosphates
In addition to using extracellular LPA and S1P as substrates, LPPs also degrade extracellular PA and C1P (62). PA and C1P are more hydrophobic than LPA and S1P, and they are not transported to a significant extent by binding to albumin and other proteins in the circulation. PA in the plasma membrane of neutrophils increases endothelial membrane permeability by stimulating intracellular tyrosine kinases (79) ; this process is suppressed by LPPs, which hydrolyzes the extracellular PA. Overexpression of LPPs in HEK293 cells increases the degradation of extracellular PA and the consequent uptake of DG into the cells (80) . Exogenously added C1P increases the intracellular concentrations of C1P (81) . This is partly explained since the LPPs dephosphorylate exogenous C1P to produce ceramides, which can be phosphorylated back to C1P once they enter the cells. C1P activates cytosolic PLA 2 activity, which leads to arachidonate production and increased prostaglandin E2 synthesis in human alveolar epithelial cells (81).
Noncatalytic actions of LPPs
In addition to its phosphatase activity, human LPP3 interacts with integrins at the plasma membrane. This interaction relies on an arginine-glycine-aspartate (RGD) recognition motif on LPP3, which is located at the second extracellular loop between transmembrane α-helices III and IV.
Endothelial cell-to-cell adhesion is promoted by binding of LPP3 to integrins, especially α v β 3 and 
Intracellular functions of LPPs
LPPs are also localized on the internal membranes including the endoplasmic reticulum (84) LPPs. Therefore, PA should not be hydrolyzed unless it can be efficiently transported to the luminal sides of organelles. Although the evidence listed above strongly suggests a potential role of LPPs in regulating intracellular PA accumulation, it is still not clear how the PA is able to access to the intracellular LPPs.
Furthermore, increasing the expression of LPP1 in fibroblasts decreases the effects of LPA and PDGF in activating PLD, which provides an alternative explanation of the observed decrease in steady-state PA concentrations (60). Actually, the lipin family of phosphatidate phosphatases are now thought to provide the capacity for degrading PA on the cytosolic surface of membranes (93).
LPPs also degrade intracellular C1P and S1P. Both C1P and S1P are involved in inflammation.
C1P activates PLA 2 to produce arachidonate, and S1P activates cyclooxygenase-2, which convert arachidonate to prostaglandin E 2 (81) . S1P in the nucleus binds specifically to the histone deacetylases, HDAC1 and HDAC2, and inhibits their enzymatic activities thus activating gene transcription (94). S1P
is also an activator of E3 ligase activity and thereby regulates TNF-α signaling (95). In addition, the levels of ceramide and S1P inside cells determine the apoptotic signaling versus cell proliferation (96).
These S1P-mediated processes could be regulated by the LPPs or the two specific intracellular S1P phosphatases, which are structurally related to the LPPs. expression on the progression of cells through S-phase of the cell cycle (100). These investigators also compared data from a genomic screen between normal and transformed mesenchymal stem cells.
PPAP2C/LPP2 was identified as one target whose expression is elevated in numerous carcinomas and sarcomas (100) . In contrast to the targeting of LPP1 and LPP2, knockdown of LPP3 (Ppap2C) in mice produces a very severe phenotype resulting in embryo death around E9. (102, 103) .
These combined results demonstrate that individual LPPs have distinct functions that cannot be replaced by other family members. The work also shows that the LPPs appear to control cell migration through a signaling system that may be conserved between flies and mammals.
The role of LPPs in pathology
This section will concentrate on the LPPs in mammals while recognizing that the LPPs have a significant role in plant physiology and pathology (105) . A significant portion of our knowledge concerning the physiological and pathological functions of the LPPs comes from studies on the functions of the LPPs in the vasculature and cancer.
LPP3 and the vasculature
Studies have already indicated the close relationship between LPP3 and vascular system. Strong evidence comes from the phenotype of PPAP2B/LPP3 knockout mice. The mice have a deletion of exon 5 in the LPP3 gene that encodes one of its catalytic domains (101) . Knockout mice die between E7.5 and 9.5 and do not form a chorio-allantoic placenta and yolk sac vasculature. A subset of embryos show a shortening of the anterior-posterior axis that was similar to that in axin deficiency, a critical regulator of Wnt signaling. Loss of LPP3 activity results in decreased transcription through the β-catenin-mediated T cell transcription factor (TCF), whereas elevated levels of LPP3 produced the opposite effect (101). This action did not appear to depend totally upon the phosphatase activity of LPP3 since a catalytically inactive LPP3 mutant was partially effective in inhibiting TCF/β-catenin transcription in HEK293 cells.
Additional support for a role of LPP3 in axis patterning was provided from the observations that ectopic expression of LPP3 in dorsal blastomeres of Xenopus embryos causes a mild ventralizing effect (101).
Furthermore, axis duplication by Xwnt8 or Xwnt3a mRNA is inhibited by co-injection of LPP3 mRNA.
Further work is performed using heterozygous embryos carrying a β-galactosidase reporter gene to monitor the expression pattern of LPP3 in different stages (106) . The earliest expression of LPP3 in vessels is seen on vascular mesodermal cells of the yolk sac in E8. 
Role of the ATX-LPA-LPP axis in cancer
LPPs have the potential regulate tumor progression since LPA signaling is involved at multiple levels in this process. To understand the potential regulatory effects of the LPPs, we will first discuss the relation of ATX activity and LPA production in cancer. LPA also adversely affects cancer therapies by producing resistance to the cytotoxic effects of Taxol (125, 135, 136) , a common first line treatment for breast cancer. This work was confirmed (137) and extended to LPA-induced resistance to carboplatin (138) and radiation-induced cell death (125, 139, 140) . LPA also attenuates doxorubicin-induced killing of breast cancer cells. This results partly from the LPA-induced increase in the stability of the transcription factor, Nrf2, which stimulates the anti-oxidant response element to increase the expression of the multidrug resistant transporters, ABCC1 and ABCG2, and anti-oxidant genes (141) . The anti-oxidant enzymes decrease the extent of oxidative damage produced by many chemotherapeutic agents. Increased expression of multidrug resistant transporters facilitates the export of several chemotherapeutic agents, including doxorubicin, and also toxic oxidation products, thus contributing to chemo-resistance. ABCC1 and ABCG2 might also facilitate the secretion of S1P, especially if the S1P transporter, spinster homolog-2, is absent (142) . This S1P secretion contributes to chemo-resistance (143) and it stimulates of angiogenesis, which is required by the growing tumor.
Thus LPA and S1P coordinate the tumor growth (125, 139) and the invasion of breast cancer cells into surrounding tissue to form metastases (121) . Blocking signaling by LPA (144) or S1P (65, 145) has, therefore, been proposed as important therapeutic targets for the treatment of cancer. We recently showed that inhibition of ATX and LPA formation decreases breast tumor growth and metastasis and increases the efficacy of doxorubicin therapy (141, 146) . Blocking the formation of S1P using inhibitors of sphingosine kinase-1 (147), or increasing S1P breakdown through S1P lyase (148) also has therapeutic potential for cancer treatment.
An alternative approach to targeting LPA signaling is to increase LPA and S1P degradation through the LPPs, which could also decrease their abilities to signal downstream of receptor activation in cancer cells. This can be achieved by increasing the low levels of expression of LPP1 and LPP3, which are observed in several types of cancer from the analysis of gene arrays published in (149-151) and accessed through Oncomine™ (152, 153) (Fig. 3) . In support of this hypothesis, overexpressing LPP1 in ovarian cancer cell lines increases LPA hydrolysis. This is associated with a marked inhibition of cell proliferation and colony-forming activity and increased apoptosis (154) . LPP3 shows similar effects in SKOV3 and OVCAR-3 ovarian cancer cells. LPP3 promotes LPA hydrolysis in the medium and decreases LPA-stimulated colony formation. This effect of LPP3 depends on its "ecto-activity" and this effect was diminished by using a non-hydrolyzable LPA analogue instead of LPA (99) . Gonadotropinreleasing hormone increases ecto-LPP expression in ovarian cancer cells and this explains its antiproliferative effects (155) . These studies with cultured cancer cells were validated by measuring tumor growth from SKOV3 ovarian carcinoma cells in nude mice. Cells with over-expressed hLPP3 showed much lower tumor growth (99) . The authors ascribed this result to the ecto-phosphatase activities of LPP3 at a time when the effects, which occur downstream of receptor activation, were not widely appreciated.
We expressed LPP1 and a catalytically inactive mutant, LPP1(R217K), using a doxycyclineinducible promoter in various cancer cells and determined their phenotypes (73 Therefore, the major effects of LPP1 cannot be explained by the degradation of exogenous LPA. Instead, the results put emphasis on the post-receptor signaling effects of LPP1 (Fig. 2) .
Zhao et al. also showed that LPP1 expressed in human bronchial epithelial cells inhibits Ca 2+ -transients and phosphorylation of inhibitory kappa B, followed by NF-κB activation and decreased interleukin-8 production (156) . This work identified a potential role of LPP1 in the regulation of LPAinduced inflammation, which is a major driving stimulus in tumor growth, metastasis and chemoresistance (57, 144).
We Intraperitoneal injection of syngeneic ovarian cancer cells into LPP1 knockout mice leads to enhanced cancer cell seeding compared to wildtype mice (157) . Presumably, higher systemic levels of LPA can explain this result as a consequence of decreased LPA turnover in LPP1 knockout mice compared to wildtype controls (58, 157). Another study showed that mice lacking LPA 1 or LPA 5 receptors had decreased melanoma-derived lung metastasis compared to wildtype mice following tail-vein injection of B16F10 melanoma cells (158) . These experiments demonstrate the importance of LPA signaling for establishing a suitable environment for cancer cell seeding and subsequent growth.
The effects of LPP2 on tumor growth appear to be quite different from LPP1 and LPP3. Flanagan et al. compared the data from a genomic screen between normal and transformed mesenchymal stem cells and identified PPAP2C/LPP2 as a target whose expression is elevated in numerous carcinomas and sarcomas. This increase in LPP2 is seen in breast, lung and ovarian cancers where the expression of LPP1 and LPP3 are decreased (Fig. 3) . Overexpressing LPP2 leads to premature S-phase entry, and this effect is not seen with LPP1 and LPP3 (98). Knockdown of LPP2 delays entry into S-phase (98) and impairs anchorage-dependent growth (100). This combined work provides preliminary evidence that increasing the low expressions of LPP1 and LPP3 and decreasing the high expression of LPP2 in cancer cells could provide novel targets for cancer therapy.
Conclusion
LPPs play an important role in regulating LPA/S1P signaling through the degradation of these 
